CGEM — Cullinan Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $816.50m
- $438.60m
- 35
- 25
- 79
- 44
Annual income statement for Cullinan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 18.9 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 86.9 | -145 | 191 | 197 | 242 |
| Operating Profit | -68 | 145 | -191 | -197 | -242 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -67.5 | 151 | -169 | -167 | -220 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -67.5 | 109 | -155 | -168 | -220 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -65.6 | 111 | -153 | -167 | -220 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -65.6 | 111 | -153 | -167 | -220 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.52 | -1.45 | -3.68 | -3.11 | -3.72 |